Organs On Chips: The Silver Bullet Pharma Is Priming To Fire
Executive Summary
In this two-part series, In Vivo will explore why organ on chip technology exists, the factors driving and limiting their application in drug development, and how companies can benefit from using them.
You may also be interested in...
Keeping Track: AZ’s Imjudo, J&J’s Tecvayli Enter Burgeoning Immuno-Oncology Market; Genmab Submits Epcoritamab
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
J&J Refines Direction For Ottava
Delays have plagued J&J's soft tissue surgical robot. However, the company has now solidified at least its near-term plan and hopes to commence trials later this year.
J&J Refines Direction For Ottava
Delays have plagued J&J's soft tissue surgical robot. However, the company has now solidified at least its near-term plan and hopes to commence trials later this year.